Edition:
United States

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

174.64USD
3:36pm EDT
Change (% chg)

$2.43 (+1.41%)
Prev Close
$172.21
Open
$173.40
Day's High
$175.53
Day's Low
$172.32
Volume
60,680
Avg. Vol
114,204
52-wk High
$175.60
52-wk Low
$95.16

Select another date:

Thu, Sep 28 2017

Abiomed invests in Israeli medical device maker Magenta

JERUSALEM Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc, a maker of catheter-based heart pumps, and venture capital firm Pitango.

Abiomed invests in Israeli medical device maker Magenta

JERUSALEM, Sept 28 Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc , a maker of catheter-based heart pumps, and venture capital firm Pitango.

BRIEF-Abiomed receives FDA PMA approval for Impella RP for right heart failure

* Abiomed receives FDA PMA approval for Impella RP for right heart failure Source text for Eikon: Further company coverage:

BRIEF-Abiomed maintains fiscal year 2018 revenue guidance

* Says ‍is maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million - SEC filing​

BRIEF-ABIOMED says CFO Michael Tomsicek resigns

* ABIOMED announces resignation of chief financial officer and welcomes back former chief financial officer as consultant

BRIEF-Abiomed Q1 gaap earnings per share $0.82

* Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29% over prior year

BRIEF-Abiomed reports Q1 EPS $0.82

* Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29 pct over prior year

BRIEF-New study with Abiomed's Impella 2.5 Heart Pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery

* New study with Abiomed's Impella 2.5® heart pump demonstrates potential survival with pre-PCI insertion in heart attacks with the left main coronary artery Source text for Eikon: Further company coverage:

BRIEF-Abiomed says enrolled first patient in FDA approved prospective feasibility study

* Abiomed - enrollment of first patient in fda approved prospective feasibility study, STEMI door to unloading with Impella CP system in acute myocardial infarction

BRIEF-Abiomed Q4 gaap earnings per share $0.33

* Abiomed announces Q4 fy 2017 revenue of $124.7 million, up 33% over prior year and total year revenue of $445.3 million, up 35% over prior year

Select another date: